High-Tc Susceptometer to Monitor Transfusional Iron Overload
NCT01241357 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99
Last updated 2016-09-21
Summary
The proposed research project will continue the application and development of a new method (biomagnetic susceptometry) that measures magnetic fields to determine how much iron is in the liver. The amount of iron in the liver is the best indicator of the amount of iron in the whole body. Measuring the amount of iron in the body is important because either too much (iron overload) or too little iron (iron deficiency) can be harmful. At present, the most reliable way to measure the amount of iron in the liver is to remove a sample of the liver by biopsy, either by surgery or by using a needle which pierces the skin and liver. Iron stored in the liver can be magnetized to a small degree when placed in a magnetic field. In patients with iron overload, the investigators previous studies have shown that magnetic measurements of liver iron in patients with iron overload are quantitatively equivalent to biochemical determinations on tissue obtained by biopsy. In the past the investigators have developed a device to measure the amount of magnetization, which was called a SQUID (Superconducting QUantum Interference Device) susceptometer. This device was validated and in use for over 20 years. The safety, ease, rapidity and comfort of magnetic measurements make frequent, serial studies technically feasible and practically acceptable to patients. The investigators have now developed a new susceptometer, which uses very similar technology to the SQUID, but the investigators believe is more accurate and precise. This study aims to validate this new instrument. The investigators will do prospective, serial studies of the diagnosis and management of patients with iron overload, including thalassemia major (Cooley's anemia), sickle cell disease, aplastic anemia, myelodysplasia, hereditary hemochromatosis, and other disorders. Funding Source - FDA OOPD.
Conditions
- Transfusional Iron Overload
- Thalassemia Major
- Sickle Cell Disease
- Myelodysplastic Syndromes
- Aplastic Anemia
Interventions
- DEVICE
-
Hepatic biomagnetic susceptibility measurement
Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Gary M. Brittenham, M.D. · Columbia University
Eligibility
- Min Age
- 5 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-03-31
- Primary Completion
- 2015-10-31
- Completion
- 2016-05-31
Countries
- United States
Study Locations
More Related Trials
-
Genes Influencing Iron Overload State
NCT01158794 ·Status: COMPLETED
-
Deferoxamine for the Treatment of Hemochromatosis
NCT00001203 ·Status: COMPLETED
-
Effect of Iron Status on Occurrence of Non-transferrin-bound Iron (NTBI) in Serum in Response to an Oral Iron Load
NCT02831712 ·Status: UNKNOWN ·Phase: NA
-
Iron Status in BTM With Blood Transfusion
NCT04947540 ·Status: UNKNOWN
-
Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter
NCT00481221 ·Status: UNKNOWN
-
Effects of Transfusion of Older Stored Red Cells
NCT01534676 ·Status: TERMINATED ·Phase: NA
-
PICU Transfusion Study: Harmful Effects of Red Blood Cell Transfusions
NCT02087553 ·Status: COMPLETED
-
Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome
NCT02262312 ·Status: COMPLETED
-
Non-invasive Optical Detection of Iron Deficiency in Children
NCT02701309 ·Status: COMPLETED
-
Multi-Center Study of Iron Overload: Pilot Study
NCT01114776 ·Status: COMPLETED
-
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00000595 ·Status: COMPLETED ·Phase: PHASE2
-
Utility of Fibroscan in Estimating Hepatic Iron Concentration
NCT02067130 ·Status: UNKNOWN ·Phase: NA
-
MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfusions.
NCT00629291 ·Status: COMPLETED
-
Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients
NCT05355766 ·Status: COMPLETED ·Phase: PHASE2
-
"Iron Overload and Endocrinological Diseases"
NCT06137079 ·Status: RECRUITING
-
Evaluation of the Free α-hemoglobin Pool in the Red Blood Cells : Prognostic Marker and Severity Index in Thalassemic Syndromes
NCT02855957 ·Status: COMPLETED ·Phase: NA
-
Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
NCT01709032 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT00512564 ·Status: COMPLETED
-
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
NCT00981370 ·Status: TERMINATED ·Phase: PHASE3
-
Determination of Iron Absorption and Losses in People Living at High Altitude to Investigate the Requirements in This Population Group Using a Newly Developed Technique
NCT07142590 ·Status: RECRUITING ·Phase: NA
-
Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure
NCT01925703 ·Status: COMPLETED ·Phase: PHASE4
-
Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement
NCT02957643 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Iron Interventions and Non-transferrin-bound Iron (NTBI) in Women
NCT01404533 ·Status: COMPLETED ·Phase: NA
-
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
NCT01239901 ·Status: COMPLETED
-
Treatment of Hemochromatosis
NCT00007150 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2